Investors eyeing opportunities in the healthcare sector may find Organon & Co. (NYSE: OGN) an intriguing prospect. Despite facing certain challenges, the company’s stock analysis reveals potential upside, making it a candidate for those willing to take calculated risks in their portfolio.

**Company Overview**

Organon & Co., headquartered in Jersey City, New Jersey, operates within the healthcare sector, specializing in general drug manufacturing. The company boasts a diverse portfolio of health solutions, including prescription therapies and medical devices. Their offerings span across women’s health, biosimilars, and various therapeutic areas, serving regions such as the United States, Europe, and Asia-Pacific.

**Current…